Rocket Pharmaceuticals Inc. (RCKT)
NASDAQ: RCKTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 2.69 +2.13%
RCKT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $288.71M
- EPS (TTM)
- -$0.17
- Dividend yield
- None
- 52-week range
- 2.42 – 5.45
- Day range
- 2.52 – 2.77
- Volume / Avg
- 3.45M / 1.66M
- Beta
- —
- Shares outstanding
- 109.77M
- Next earnings
- Nov 5, 2026
52-week range
RCKT stock today
Rocket Pharmaceuticals (RCKT) closed at $2.63 on Oct 8, up 3.75% (+$0.095), versus the S&P 500's 0.47% decline. Volume was 2.1x the average at 3.45M shares, a sign of unusually heavy trading. At this level, RCKT sits near the bottom of its 52-week range of $2.42 to $5.45: 51.7% below the high, set on Mar 10, 2026 and 8.7% above the low.
RCKT is down 27.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 19.3%. Rocket Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.17), so its P/E ratio is not meaningful. Rocket Pharmaceuticals's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Rocket Pharmaceuticals
Company profileRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Gaurav D. Shah M.D.
- Headquarters
- Cranbury, NJ
- Employees
- 202
- IPO year
- 2015
- Website
- rocketpharma.com
Analyst forecast
ForecastConsensus (14 analysts)
buy
Avg. price target
$8.50+223.19%
- Strong buy 1
- Buy 6
- Hold 5
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.39
RCKT news
All RCKT newsRocket Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LRMRLarimar Therapeutics Inc. | 2.70 | -1.82% | $280.48M | vs RCKT |
| BBOTBridgeBio Oncology Therapeutics Inc. | 3.42 | -0.58% | $274.20M | vs RCKT |
| VNDAVanda Pharmaceuticals Inc. | 4.53 | -0.66% | $273.90M | vs RCKT |
| ABEOAbeona Therapeutics Inc. | 4.96 | -2.36% | $283.63M | vs RCKT |
| BIOABioAge Labs Inc. | 6.21 | -0.80% | $285.02M | vs RCKT |
| FULCFulcrum Therapeutics Inc. | 3.75 | +2.18% | $286.11M | vs RCKT |
| BCYCBicycle Therapeutics plc ADR | 3.81 | +2.14% | $266.67M | vs RCKT |
| VOGXVogenx Inc | 17.49 | +8.23% | $259.82M | vs RCKT |
Indexes, lists and sector
Rocket Pharmaceuticals stock FAQ
What is Rocket Pharmaceuticals's stock price today?
RCKT last traded at $2.63 as of Oct 8, 4:00 PM EDT, up 3.75% on the day. Prices are delayed at least 15 minutes.
Does Rocket Pharmaceuticals pay a dividend?
No. Rocket Pharmaceuticals does not currently pay a regular cash dividend.
When is Rocket Pharmaceuticals's next earnings date?
Rocket Pharmaceuticals is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.39.
Who is Rocket Pharmaceuticals's CEO?
Dr. Gaurav D. Shah M.D. is the chief executive officer of Rocket Pharmaceuticals Inc., which has about 202 employees.
Has RCKT ever split its stock?
Yes. The most recent RCKT stock split was a 1-for-4 split on Jan 5, 2018.
What is the RCKT 52-week high?
The 52-week high for RCKT is $5.45 and the 52-week low is $2.42. The stock is currently 51.7% below its high.